Sun City, AZNCT07064759Now EnrollingIRB Ready

Age-Related Macular Degeneration Clinical Trial in Sun City, AZ

Access cutting-edge age-related macular degeneration treatment through this phase 3 clinical trial at a research site in Sun City. Study-provided care at no cost to qualified participants.

Sponsored by 4D Molecular Therapeutics

Quick Self-Assessment

See if you qualify for this Sun City location

Preparing your pre-screening questions…

Expert Care in Sun City

Access age-related macular degeneration specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related age-related macular degeneration treatment provided free

Apply for This Sun City Location

Check if you qualify for this age-related macular degeneration clinical trial in Sun City, AZ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Sun City

    Convenient for AZ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Sun City site if eligible
  4. 4Begin participation

About This Age-Related Macular Degeneration Study in Sun City

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

Sponsor: 4D Molecular Therapeutics

Who Can Participate

Inclusion Criteria

≥50 years of age at time of consent
MNV secondary to nAMD with IVT anti-VEGF treatment history in the study eye, defined as EITHER:
Treatment naïve, i.e. no prior IVT anti-VEGF therapy OR
Previously treated with no more than 4 IVT anti-VEGF injections due to nAMD and received diagnosis of nAMD no more than 6 months prior to the Screening Visit AND documented evidence of anatomical improvement and visual stability/improvement in response to previous IVT anti-VEGF treatment, as determined by the Investigator
Active subfoveal MNV or juxtafoveal/ extrafoveal MNV with a subfoveal component (where activity is defined as evidence of SRF, IRF, subretinal hyperreflective material, or leakage) identified by fluorescein angiography (FA) or spectral domain optical coherence tomography (SD-OCT) , in the study eye, at the Screening Visit confirmed by the Reading Center
Demonstrated clinical response to aflibercept and functional stability in the study eye as confirmed by the Reading Center
BCVA between 25 and 78 ETDRS letters, inclusive (20/320-20/32 Snellen equivalent) in the study eye at the Screening Visit
CST less than or equal to 500 microns in the study eye at screening visit, confirmed by the central reading center

Exclusion Criteria

Ocular Conditions:
MNV due to causes other than nAMD in either eye (Fibrosis, atrophy, or subretinal hemorrhage in the foveal central subfield (1 mm diameter)
History of retinal detachment in the study eye
History of or presence of active inflammation in either eye
Glaucoma or intraocular hypertension requiring more than 2 topical medications for control Ocular Treatments/Interventions:
Any prior or concomitant treatment for MNV or vitreomacular-interface abnormalities, other than allowed prior IVT anti-VEGF in the study eye Systemic Conditions and Considerations:
Major illness or major surgical procedure in the 28 days prior to the Screening Visit
Uncontrolled blood pressure
Acute coronary syndrome, myocardial infarction or coronary artery revascularization, cerebrovascular accident, transient ischemic attack within 6 months of the Screening Visit
History of autoimmune condition that may predispose to the development of uveitis

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Sun City?

Yes, this clinical trial (NCT07064759) has an active research site in Sun City, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Age-Related Macular Degeneration Treatment Options in Sun City, AZ

If you're searching for age-related macular degeneration treatment options in Sun City, AZ, this clinical trial (NCT07064759) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Sun City research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced age-related macular degeneration specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all age-related macular degeneration clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Sun City, AZ

See all rheumatoid arthritis clinical trials recruiting in Sun City — not just this study.

Browse Rheumatoid Arthritis Trials in Sun City →

Ready to Join in Sun City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Sun City, AZ